FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast Cancer
Efficacy and safety were evaluated in the ASCENT study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
EMA Recommends Granting a Marketing Authorisation for Duvelisib
PI3K inhibitor is intended for the treatment of relapsed or refractory chronic lymphocytic leukaemia and refractory follicular lymphoma
Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal Cancer in FAP
Findings from a randomised J-FAPP Study IV in patients with familial adenomatous polyposis
FDA Approves Idecabtagene Vicleucel for Multiple Myeloma
Idecabtagene vicleucel is a BCMA-directed genetically modified autologous CAR T-cell therapy
Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal Junction Cancer
The CheckMate 577 study results show double longer disease-free survival with adjuvant nivolumab after neoadjuvant chemoradiotherapy and resection
EMA Recommends Extension of Indications for Enzalutamide
New indication concerns the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy
Delayed irAEs Occur in a Small Subset of Patients with Melanoma, but Often High Grade and Difficult to Manage
Further work is needed to identify patients who are most at risk of delayed immune-related adverse events to anti-PD1 therapy
Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in Hypermutated Tumours
In tumours with high mutational burden treated with ICI, improved overall survival associated mainly with mutations in the POLE gene and with defective DNA mismatch repair
FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma
Evidence for efficacy is based on the results of KEYNOTE-590 study
EMA Recommends Extension of Indications for Atezolizumab
New indication concerns first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression
Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in Patients with Early Stage NSCLC
Results from the ASTEROID study with durvalumab after stereotactic body radiotherapy in patients with early stage non-small cell lung cancer
Olaparib Maintenance Fails in Platinum Sensitive Advanced Non-Small Cell Lung Cancer
Results from early halted PIPSeN study in chemonaïve patients with non-small cell lung cancer without EGFR or ALK/ROS alterations